Targeting the cancer initiating cell: The Achilles' heel of cancer

Advances in Enzyme Regulation

Volumn 51, Issue 1, 2011, Pages 152-162

  McCubrey, James A ^a   Chappell, William H ^a   Abrams, Stephen L ^a   Franklin, Richard A ^a   Long, Jacquelyn M ^b   Sattler, Jennifer A ^b   Kempf, C Ruth ^b   Laidler, Piotr ^c   Steelman, Linda S ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ARTICLE; CANCER STEM CELL; CELL TRANSFORMATION; DIET SUPPLEMENTATION; DRUG RESISTANCE; DRUG SCREENING; HUMAN; MALE; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DIETARY SUPPLEMENTS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; NEOPLASMS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79954544680     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2010.09.002     Document Type: Article

References (72)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
2. Allred C.D., Allred K.F., Ju Y.H., Virant S.M., Helferich W.G. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 2001, 61:5045-5050.
3. Ariga A., Namekawa J., Matsumoto N., Inoue J., Umezawa K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002, 277:24625-24630.
4. Attard G., Clark J., Ambroisine L., Fisher G., Kovacs C., Flohr P., et al. Duplication of the fusion of TMPRSS2 to ERGsequences identifies fatal human prostate cancer. Oncogene 2008, 27:253-263.
5. Badger T.M., Ronis M.J.J., Simmen R.C.M., Simmen F.A. Soy protein isolate and protection against cancer. J AmericanCollege Nutr 2005, 24:146S-149S.
6. Banerjee S., Li Y., Wang Z., Sarkar F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett 2008, 269:226-242.
7. Barjesteh van Waalwijk van Doorn-Khosrovani S., Janssen J., Maas L.M., Godschalk R.W.L., Nijhuis J.G., van Schooten F.J. Dietary flavonoids induce MLL translocations in primary human CD34+ cells. Carcinogenesis 2007, 28:1703-1709.
8. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
9. Bracarda S., de Gobelli O., Greco C., Prayer-Galetti T., Valdagni R., Gatta G., et al. Cancer of the prostate. Crit reviews Oncology/hematology 2005, 56:379-396.
10. Chan J.M., Gann P.H., Giovannucci E.L. Role of prostate cancer development and progression. J Clin Oncol 2005, 23:8152-8160.
11. de Lemos M.L. Effects of soy phtoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 2001, 35:11118-11121.
12. Donohue J.F., Bianco F.J., Kuroiwa K., Vickers A.J., Wheeler T.M., Scardino P.T., et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 2006, 176:991-995.
13. Franklin R., Rodriquez-Mora O., La Hair M., McCubrey J.A. Activation of the Calcium/Calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signaling 2006, 8:1807-1817.
14. Han M., Partin A.W., Pound C.R., Epstein J.I., Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomical radical retropubic pubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-565.
15. Hermann R.M., Wolff H.A., Jarry H., Thelen P., Gruendker C., Rave-Fraenk M., et al. In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol. Radiat Oncol 2009, 3:19.
16. Hillman G.G., Forman J.D., Kucuk O., Yudelev M., Maughan R.L., Rubio J., et al. Genistein potentiates the radiation effect on prostate cancer cells. Clin Cancer Res 2001, 7:382-390.
17. Hillman G.G., Wang Y., Kucuk O., Che M., Doerge D.R., Yudelev M., et al. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004, 3:1271-1279.
18. Hollier B.G., Evans K., Mani S.A. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009, 14:29-43.
19. Hooper L, Madhavan G, Tice JA, Leinster SJ, Cassidy A. Effects of isoflavones on breast cancer density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Human Reproduction Update, in press.
20. Hsieh C.Y., Santell R.C., Haslam S.Z., Helferich W.G. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998, 58:3833-3838.
21. Hsu A., Bray T.M., Ho E. Anti-inflammatory activity of soy and tea in prostate cancer progression. Exp Biol Med 2010, 235:659-667.
22. Itsiopoulos C., Hodge A., Kaimakamis M. Can the Mediterranean diet prevent prostate cancer?. Mol Nutr Food Res 2009, 53:227-390.
23. Ju Y.H., Doerge D.R., Allred K.F., Allred C.D., Helferich W.G. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002, 62:2474-2477.
24. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707-712.
25. Kumar S.K., Roy I., Anchoori R.K., Fazli S., Maitra A., Beachy P.A., et al. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg Med Chem 2008, 16:2764-2768.
26. LaHair M.M., Howe C.J., Rodriguez-Mora O., McCubrey J.A., Franklin R.A. Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. Antioxid Redox Signaling 2006, 8:1749-1756.
27. Lakshman M., Xu L., Ananthanarayanan V., Cooper J., Takimoto C.H., Helenowski I., et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 2008, 68:2024-2032.
28. Lampe J.W. Is equol the key to the efficacy of soy foods?. Am J Clin Nutr 2009, 89:1664S-1667S.
29. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
30. Lawson D.A., Witte O.N. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007, 117:2044-2050.
31. Lee J.T., Lehmann B.D., Terrrian D.M., Chappell W.H., Stivala F., Libra M., et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008, 7:1745-1762.
32. Lehmann B.D., McCubrey J.A., Jefferson H.S., Paine M.S., Chappell W.H., Terrian D.M. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 2007, 6:595-605.
33. Lehmann B.D., McCubrey J.A., Terrian D.M. Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biol Ther 2007, 6:1165-1170.
34. Li X., Choi J.-S. Effect of genistein on the pharmacokinetic of paclitaxel administere orally or intravenously in rats. Int J Pharmaceutics 2007, 337:188-193.
35. Li Y., Kucuk O., Hussain M., Abrams J., Cher M.L., Sarkar F.H. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of nuclear factor-kappaB(RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res 2006, 66:4816-4825.
36. Ligresti G., Militello L., Steelman L.S., Cavallaro A., Basile F., Nicoletti F., et al. PIK3CA mutations in human solid tumors. Cell Cycle 2009, 8:1352-1358.
37. Mailtand N.J., Collins A.T. Prostate cancer stem cells: a new target of therapy. J Clin Oncol 2007, 26:2862-2870.
38. Messina M., Watanabe S., Setchell K.D.R. Report of the 8th international symposium on the role of soy in helath promotion and chronic disease prevention and treatment. J Nutr 2009, 22:790S-802S.
39. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
40. Marian C.O., Shay J.W. Prostate tumor-initiating cells: a new target for telomerase inhibition therapy?. Biochim Biophys Acta 2009, 1792:289-296.
41. Martelli A.M., Evangelisti C., Chiarini F., Grimaldi C., Manzoli L., McCubrey J.A. Targeting the PI3K/Akt/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009, 18:1333-1349.
42. Martelli A.M., Evangelisti C., Chiarini F., Grimaldi C., Cappellini A., Ognibene A., et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 2010, 1803:991-1002.
43. Martelli A.M., Evangelisti C., Chiarini F., Grimaldi C., McCubrey J.A. The emerging role of the phsophatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers 2010, 2:1567-1596.
44. McCubrey J.A., Shelton J.G., Steelman L.S., Franklin R.A., Sreevalsan T., McMahon M. Conditionally active v-ErbB: ER transforms NIH-3T3 cells and converts human and mouse cells to cytokine-independence. Oncogene 2004, 23:7810-7820.
45. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 177:1263-1284.
46. McCubrey J.A., Steelman L.S., Abrams S.L., Chappell W.H., Russo S., Ove R., et al. Emerging Raf inhibitors. Exp Opin Emerging Drugs 2009, 14:633-648.
47. McCubrey J.A., Steelman L.S., Abrams S.L., Chappell W.H., Russo S., Ove R., et al. Emerging MEK inhibitors. Exp Opin Emerging Drugs 2010, 15:203-223.
48. McCubrey J.A., Abrams S.L., Stadelman K., Chappell W.H., LaHair M., Ferland R.A., et al. Targeting signal transduction pathways to eliminate drug resistance and cancer stem cells. Adv Enzym Regul 2010, 50:285-307.
49. Messina M. Soybean isoflavone exposure does not have feminizing effects on men: a critical examination of the clinical evidence. Fertil Sterility 2010, 93:2095-2104.
50. Mimeault M., Johansson S.L., Henichart J.P., Depreux P., Batra S.K. Cytotoxic effects induced by docetaxel gefitinib and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther 2010, 9:617-628.
51. Park C.U., Jeong M.K., Park M.H., Yeu J.D., Park M.S., Kim M.J., et al. Formation of succinyl genistin and succinyl daidzin by Bacillus species. J Food Sci 2010, 75:C128-133.
52. Penson D.F., Chan J.M. Prostate cancer. J Urol 2007, 177:2020-2029.
53. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cells. Nat Rev Cancer 2009, 9:265-273.
54. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following a radical prostatectomy. JAMA 1999, 281:1591-1597.
55. Raffoul J., Wang Y., Kucuk O., Forman J.D., Sarkar F.H., Hillman G.G. Genistein inhibits it radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006, 6:107.
56. Raffoul J.J., Banerjee S., Che M., Knoli Z.E., Doerge D.R., Abrams J., et al. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer 2007, 120:2491-2498.
57. Raffoul J.J., Banerjee S., Sing-Gupta V., Knoll Z.E., Fite A., Zhang H., et al. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007, 67:2141-2149.
58. Ravindranth M.H., Mutgounder S., Presser N., Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 2004, 546:121-165.
59. Rodriguez-Mora O., LaHair M.M., Howe C.J., McCubrey J.A., Franklin R.A. The Calcium/Calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opin Ther Targets 2005, 9:791-808.
60. Saadane A., Masters S., DiDonato J., Li J., Merger M. Parthenolide inhibits IκB kinase, NF-κB activation and inflammatory response in cyctic fibrosis cells and mice. Am J Respir Cell Mol Biol 2007, 36:728-736.
61. Sanchez C., Mendoza P., Contreras H.R., Vergara J., McCubrey J.A., Huidobro C., et al. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 2009, 69:1448-1459.
62. Shay J.W. Prostate tumor-initiating cells: a new target for telomerase inhibition therapy?. Biochim Biophys Acta 2009, 1792:289-296.
63. Shelton J.G., Steelman L.S., Lee J.T., Knapp S.L., Blalock W.L., Moye P.M., et al. Effects of the Raf/MEK/ERK and PI3K signal transduction pathways on the abrogation of cytokine dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2004, 24:2478-2492.
64. Shelton J.G., Steelman L.S., Abrams S.L., Bertrand F.E., Franklin R.A., McMahon M., et al. The epidermal growth factor receptor as a target for therapeutic intervention in numerous cancers-What's genetics got to do with it?. Expert Opin Ther Targets 2005, 9:1009-1030.
65. Sheng T., Li C., Zhang X., Chi S., He N., Chen K., et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004, 3:29.
66. Steelman L.S., Bertrand F.E., McCubrey J.A. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 2004, 8:537-550.
67. Steelman L.S., Navolanic P.N., Sokolosky M., Taylor J.R., Lehmann B.D., Chappell W.H., et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity of mTOR inhibitors. Oncogene 2008, 27:4086-4095.
68. Steelman L.S., Stadelman K.M., Chappell W.H., Horn S., Basecke J., Cervello M., et al. Akt as a therapeutic target in cancer. Exp Opin Ther Targets 2008, 12:1139-1165.
69. Stephenson A.J., Kattan M.W., Eastham J.A., Bianco F.J., Yossepowitch O., Vickers A.J., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009, 27:4300-4305.
70. Trock B.J., Han M., Freedland S.J., Humphreys E.G., DeWeese T.L., Partin A.W., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008, 299:2760-2769.
71. Wang Y., Raffoul J.J., Che M., Doerge D.R., Joiner M.C., Kucuk O., et al. Prostate cancer treatement in enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res 2006, 166:73-80.
72. Ward J.F., Moul J.W. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005, 2:174-183.